Aprocitentan Patent Expiration
Aprocitentan was first introduced by Idorsia Pharmaceuticals Ltd
Aprocitentan Patents
Given below is the list of patents protecting Aprocitentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tryvio | US11680058 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Jul 26, 2038 | Idorsia |
| Tryvio | US11787782 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | Mar 02, 2038 | Idorsia |
| Tryvio | US10919881 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Feb 26, 2038 | Idorsia |
| Tryvio | US12297189 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Feb 26, 2038 | Idorsia |
| Tryvio | US11174247 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | Nov 06, 2037 | Idorsia |
| Tryvio | US8324232 | 4-pyrimidinesulfamide derivative | Sep 21, 2029 | Idorsia |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Aprocitentan's patents.
Latest Legal Activities on Aprocitentan's Patents
Given below is the list recent legal activities going on the following patents of Aprocitentan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 27 Jan, 2026 | US8324232 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US8324232 |
| Email Notification | 17 Sep, 2025 | US11680058 |
| Mail Patent eCofC Notification | 16 Sep, 2025 | US11680058 |
| Patent eCofC Notification | 16 Sep, 2025 | US11680058 |
| Recordation of Patent eCertificate of Correction | 16 Sep, 2025 | US11680058 |
| Post Issue Communication - Certificate of Correction | 25 Aug, 2025 | US11680058 |
| Mail Certificate of Correction Memo | 25 Aug, 2025 | US11680058 |
| Certificate of Correction Memo | 21 Aug, 2025 | US11680058 |
| Second letter to regulating agency to determine regulatory review period | 19 Aug, 2025 | US8324232 |
Aprocitentan's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Aprocitentan:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE3 |